Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713

NCT07155187 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07155187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07155187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713
Lead sponsor
AbbVie
Phase
Phase 2/3
Overall status
Recruiting
Start date
December 10, 2025
Completion date
September 30, 2030
Enrollment
490 (estimated)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

c-met, non-small cell lung cancer